Roche WN28745
Back to Drug Development Trials
![]()
Drug Development Trials
About the trial
A phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter, efficacy and safety of gantenerumab in patients with mild Alzheimer’s disease.
